(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 22.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Rigel Pharmaceuticals's revenue in 2024 is $120,346,000.On average, 4 Wall Street analysts forecast RIGL's revenue for 2024 to be $25,389,162,603, with the lowest RIGL revenue forecast at $22,259,039,927, and the highest RIGL revenue forecast at $27,121,298,295. On average, 4 Wall Street analysts forecast RIGL's revenue for 2025 to be $32,685,532,058, with the lowest RIGL revenue forecast at $28,064,983,360, and the highest RIGL revenue forecast at $34,895,298,685.
In 2026, RIGL is forecast to generate $38,480,951,122 in revenue, with the lowest revenue forecast at $35,063,688,585 and the highest revenue forecast at $40,692,471,811.